Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Neuer Top-Geologe an Bord - zündet jetzt die nächste Kursrakete?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CPQG | ISIN: US92337R1014 | Ticker-Symbol:
NASDAQ
04.06.25 | 21:59
31,990 US-Dollar
0,00 % 0,000
1-Jahres-Chart
VERA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VERA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur VERA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiScotiabank Increases the Price Target for Vera Therapeutics by $103
DiVera Therapeutics announces refinancing of Oxford debt facility with access to up to $500M in term loans1
DiVera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans3
MoVera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday17
MoTD Cowen behält Kaufempfehlung für Vera Therapeutics-Aktie bei1
MoTD Cowen maintains buy rating for Vera Therapeutics stock1
MoJPMorgan reiterates Vera Therapeutics stock rating after study data2
VERA THERAPEUTICS Aktie jetzt für 0€ handeln
MoKidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data2
MoEvercore ISI maintains outperform rating on Vera Therapeutics stock2
MoVera Therapeutics shares soar on positive Phase 3 trial results2
MoWhy Vera Therapeutics Is Rising In Pre-market?1
MoVera Therapeutics, Inc. - 8-K, Current Report1
MoVera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy83Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared...
► Artikel lesen
29.05.Cantor Fitzgerald maintains $100 target on Vera Therapeutics stock12
19.05.Vera Therapeutics, Inc. - 8-K, Current Report2
09.05.Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)173BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of non-qualified...
► Artikel lesen
06.05.Vera Therapeutics GAAP EPS of -$0.81 misses by $0.071
06.05.Vera Therapeutics, Inc. - 8-K, Current Report1
09.04.Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)224BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of...
► Artikel lesen
09.04.Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch10
Seite:  Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1